Subtype-specific differences in Gag-protease replication capacity of HIV-1 isolates from East and West Africa.


Journal

Retrovirology
ISSN: 1742-4690
Titre abrégé: Retrovirology
Pays: England
ID NLM: 101216893

Informations de publication

Date de publication:
05 05 2021
Historique:
received: 24 01 2021
accepted: 12 04 2021
entrez: 6 5 2021
pubmed: 7 5 2021
medline: 30 10 2021
Statut: epublish

Résumé

The HIV-1 epidemic in sub-Saharan Africa is heterogeneous with diverse unevenly distributed subtypes and regional differences in prevalence. Subtype-specific differences in disease progression rate and transmission efficiency have been reported, but the underlying biological mechanisms have not been fully characterized. Here, we tested the hypothesis that the subtypes prevalent in the East Africa, where adult prevalence rate is higher, have lower viral replication capacity (VRC) than their West African counterparts where adult prevalence rates are lower. Gag-protease sequencing was performed on 213 and 160 antiretroviral-naïve chronically infected participants from West and East Africa respectively and bioinformatic tools were used to infer subtypes and recombination patterns. VRC of patient-derived gag-protease chimeric viruses from West (n = 178) and East (n = 114) Africa were determined using a green fluorescent protein reporter-based cell assay. Subtype and regional differences in VRC and amino acid variants impacting VRC were identified by statistical methods. CRF02_AG (65%, n = 139), other recombinants (14%, n = 30) and pure subtypes (21%, n = 44) were identified in West Africa. Subtypes A1 (64%, n = 103), D (22%, n = 35), or recombinants (14%, n = 22) were identified in East Africa. Viruses from West Africa had significantly higher VRC compared to those from East Africa (p < 0.0001), with subtype-specific differences found among strains within West and East Africa (p < 0.0001). Recombination patterns showed a preference for subtypes D, G or J rather than subtype A in the p6 region of gag, with evidence that subtype-specific differences in this region impact VRC. Furthermore, the Gag A83V polymorphism was associated with reduced VRC in CRF02_AG. HLA-A*23:01 (p = 0.0014) and HLA-C*07:01 (p = 0.002) were associated with lower VRC in subtype A infected individuals from East Africa. Although prevalent viruses from West Africa displayed higher VRC than those from East Africa consistent with the hypothesis that lower VRC is associated with higher population prevalence, the predominant CRF02_AG strain in West Africa displayed higher VRC than other prevalent strains suggesting that VRC alone does not explain population prevalence. The study identified viral and host genetic determinants of virus replication capacity for HIV-1 CRF02_AG and subtype A respectively, which may have relevance for vaccine strategies.

Sections du résumé

BACKGROUND
The HIV-1 epidemic in sub-Saharan Africa is heterogeneous with diverse unevenly distributed subtypes and regional differences in prevalence. Subtype-specific differences in disease progression rate and transmission efficiency have been reported, but the underlying biological mechanisms have not been fully characterized. Here, we tested the hypothesis that the subtypes prevalent in the East Africa, where adult prevalence rate is higher, have lower viral replication capacity (VRC) than their West African counterparts where adult prevalence rates are lower.
RESULTS
Gag-protease sequencing was performed on 213 and 160 antiretroviral-naïve chronically infected participants from West and East Africa respectively and bioinformatic tools were used to infer subtypes and recombination patterns. VRC of patient-derived gag-protease chimeric viruses from West (n = 178) and East (n = 114) Africa were determined using a green fluorescent protein reporter-based cell assay. Subtype and regional differences in VRC and amino acid variants impacting VRC were identified by statistical methods. CRF02_AG (65%, n = 139), other recombinants (14%, n = 30) and pure subtypes (21%, n = 44) were identified in West Africa. Subtypes A1 (64%, n = 103), D (22%, n = 35), or recombinants (14%, n = 22) were identified in East Africa. Viruses from West Africa had significantly higher VRC compared to those from East Africa (p < 0.0001), with subtype-specific differences found among strains within West and East Africa (p < 0.0001). Recombination patterns showed a preference for subtypes D, G or J rather than subtype A in the p6 region of gag, with evidence that subtype-specific differences in this region impact VRC. Furthermore, the Gag A83V polymorphism was associated with reduced VRC in CRF02_AG. HLA-A*23:01 (p = 0.0014) and HLA-C*07:01 (p = 0.002) were associated with lower VRC in subtype A infected individuals from East Africa.
CONCLUSIONS
Although prevalent viruses from West Africa displayed higher VRC than those from East Africa consistent with the hypothesis that lower VRC is associated with higher population prevalence, the predominant CRF02_AG strain in West Africa displayed higher VRC than other prevalent strains suggesting that VRC alone does not explain population prevalence. The study identified viral and host genetic determinants of virus replication capacity for HIV-1 CRF02_AG and subtype A respectively, which may have relevance for vaccine strategies.

Identifiants

pubmed: 33952315
doi: 10.1186/s12977-021-00554-4
pii: 10.1186/s12977-021-00554-4
pmc: PMC8097975
doi:

Substances chimiques

gag Gene Products, Human Immunodeficiency Virus 0
HIV Protease EC 3.4.23.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

11

Subventions

Organisme : Wellcome Trust
ID : 107752/Z/15/Z
Pays : United Kingdom

Références

Lancet Infect Dis. 2019 Feb;19(2):143-155
pubmed: 30509777
Infect Dis Clin North Am. 2014 Sep;28(3):323-37
pubmed: 25151559
PLoS One. 2013 Aug 12;8(8):e71768
pubmed: 23951241
J Infect Dis. 1999 Jan;179(1):68-73
pubmed: 9841824
Virology. 2001 Sep 1;287(2):261-5
pubmed: 11531404
J Virol. 2009 Jun;83(11):5592-605
pubmed: 19297481
J Virol. 2017 Jun 9;91(13):
pubmed: 28424286
AIDS. 2006 Oct 24;20(16):W13-23
pubmed: 17053344
Nature. 2009 Apr 2;458(7238):641-5
pubmed: 19242411
AIDS. 2001 Aug;15 Suppl 4:S109-16
pubmed: 11686459
Curr HIV/AIDS Rep. 2013 Jun;10(2):111-2
pubmed: 23568544
Comput Biomed Res. 2000 Feb;33(1):84-96
pubmed: 10772786
J Virol. 2009 Dec;83(23):12636-42
pubmed: 19759140
AIDS Rev. 2012 Apr-Jun;14(2):83-100
pubmed: 22627605
Viruses. 2010 Feb;2(2):503-31
pubmed: 21994646
AIDS Res Hum Retroviruses. 2010 Oct;26(10):1087-91
pubmed: 20925575
Nature. 2008 Oct 2;455(7213):613-9
pubmed: 18833271
Retrovirology. 2013 Sep 16;10:100
pubmed: 24041011
EBioMedicine. 2016 Nov;13:305-314
pubmed: 27751765
J Virol. 2017 Aug 10;91(17):
pubmed: 28637761
J Med Virol. 2017 Jan;89(1):106-111
pubmed: 27328744
J Virol. 2011 Apr;85(8):3996-4006
pubmed: 21289112
J Infect Dis. 2014 Mar 1;209(5):721-8
pubmed: 23935204
Nature. 2004 Dec 9;432(7018):769-75
pubmed: 15592417
J Infect Dis. 2007 Apr 15;195(8):1177-80
pubmed: 17357054
AIDS. 1992 Sep;6(9):983-9
pubmed: 1388911
Virol J. 2013 Jan 22;10:29
pubmed: 23339631
J Virol. 2009 Jan;83(1):140-9
pubmed: 18971283
Biochim Biophys Acta. 2013 Feb;1828(2):816-23
pubmed: 23174350
Immunity. 2017 Jan 17;46(1):29-37
pubmed: 28087240
J Biol Chem. 2012 Dec 28;287(53):44714-35
pubmed: 23132857
J Virol. 1999 Jan;73(1):152-60
pubmed: 9847317
PLoS Pathog. 2019 Dec 6;15(12):e1007976
pubmed: 31809523
Science. 2010 Dec 10;330(6010):1551-7
pubmed: 21051598
AIDS. 2013 Nov 13;27(17):2775-86
pubmed: 24113395
J Virol. 2013 Apr;87(7):3952-65
pubmed: 23365420
J Virol. 2003 Jan;77(2):1021-38
pubmed: 12502818
J Infect Dis. 2019 Jul 2;220(3):432-441
pubmed: 30938435
Cold Spring Harb Perspect Med. 2012 Mar;2(3):a007187
pubmed: 22393534
Elife. 2016 Nov 05;5:
pubmed: 27815945
J Virol Methods. 2006 Feb;131(2):134-42
pubmed: 16182382
Open AIDS J. 2016 Apr 08;10:34-48
pubmed: 27347270
J Virol. 2010 Oct;84(20):10820-31
pubmed: 20702636
Proc Natl Acad Sci U S A. 2015 Mar 24;112(12):E1480-9
pubmed: 25730868
PLoS One. 2011 Mar 14;6(3):e17865
pubmed: 21423811
J Virol. 2020 Jul 1;94(14):
pubmed: 32376625
PLoS Pathog. 2020 Sep 14;16(9):e1008813
pubmed: 32925973
J Virol. 2002 Feb;76(3):1015-24
pubmed: 11773377
Microbes Infect. 2019 Mar;21(2):113-118
pubmed: 30385305
PLoS Pathog. 2012;8(11):e1003041
pubmed: 23209412
Retrovirology. 2010 Oct 12;7:85
pubmed: 20939905
Science. 2007 Aug 17;317(5840):944-7
pubmed: 17641165
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006841
pubmed: 22229120
Proc Natl Acad Sci U S A. 2001 May 22;98(11):6062-7
pubmed: 11353856
J Infect Dis. 2008 Mar 1;197(5):707-13
pubmed: 18266607
J Virol. 2010 Nov;84(22):11937-49
pubmed: 20810731
PLoS One. 2014 Jun 11;9(2):e98908
pubmed: 24918930
Clin Infect Dis. 2006 Mar 15;42(6):843-52
pubmed: 16477563
Nucleic Acids Res. 2009 Jul;37(Web Server issue):W647-51
pubmed: 19443440
Rev Inst Med Trop Sao Paulo. 2006 Mar-Apr;48(2):77-80
pubmed: 16699628
FEBS Lett. 1991 Apr 9;281(1-2):77-80
pubmed: 2015912
AIDS. 2009 Nov 27;23(18):2479-84
pubmed: 19841572
J Virol. 2018 Sep 12;92(19):
pubmed: 29997209
AIDS Res Hum Retroviruses. 2007 Oct;23(10):1189-96
pubmed: 17961103
Clin Infect Dis. 2002 Aug 1;35(3):313-22
pubmed: 12115098
AIDS. 2001 Feb 16;15(3):293-9
pubmed: 11273208
AIDS. 2000 Oct 20;14(15):2361-70
pubmed: 11089625
J Virol. 1998 Oct;72(10):8446-52
pubmed: 9733900
Curr Opin HIV AIDS. 2019 May;14(3):153-160
pubmed: 30882484
PLoS Pathog. 2015 Sep 17;11(9):e1005154
pubmed: 26378795
Curr Opin HIV AIDS. 2014 Sep;9(5):506-13
pubmed: 25010898

Auteurs

Omotayo Farinre (O)

HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa.

Kamini Gounder (K)

HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa.
Africa Health Research Institute, Durban, 4001, South Africa.

Tarylee Reddy (T)

Biostatistics Research Unit, South African Medical Research Council, Durban, South Africa.

Marcel Tongo (M)

Centre of Research for Emerging and Re-Emerging Diseases (CREMER), Yaoundé, Cameroon.

Jonathan Hare (J)

International AIDS Vaccine Initiative (IAVI) Human Immunology Laboratory (HIL), Imperial College, London, UK.
IAVI Global Headquarters, 125 Broad Street, 9th Floor,, New York, NY, USA.

Beth Chaplin (B)

Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Jill Gilmour (J)

International AIDS Vaccine Initiative (IAVI) Human Immunology Laboratory (HIL), Imperial College, London, UK.
IAVI Global Headquarters, 125 Broad Street, 9th Floor,, New York, NY, USA.

Phyllis Kanki (P)

Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Jaclyn K Mann (JK)

HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa.

Thumbi Ndung'u (T)

HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa. thumbi.ndungu@ahri.org.
Africa Health Research Institute, Durban, 4001, South Africa. thumbi.ndungu@ahri.org.
Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA. thumbi.ndungu@ahri.org.
Max Planck Institute for Infection Biology, Berlin, Germany. thumbi.ndungu@ahri.org.
Division of Infection and Immunity, University College London, London, UK. thumbi.ndungu@ahri.org.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH